Elysium Health has announced that it has raised $40 million in its Series C round of funding. The NYC-based company develops clinically-validated health products based on advancements in scientific research.
The debt financing was led by GISEV Family Office (Giuliani SpA/ Royalty Pharma/ HBM Healthcare/ Nogra Pharma). The round saw the participation of Mayo Clinic Ventures, Stemcentrx, Health IQ, Practice Fusion, and Western Technology Investment. General Catalyst, Morningside Ventures, and Breyer Capital were among the return investors.
“We consider ourselves privileged at Elysium to work with the world's best healthcare investors,” said Elysium Health CEO Eric Marcotulli. “Finding those who support innovation, industry-leading quality, and an approach to product development that is rooted in science has been critical to our success. We look forward to working with our financial partners and our scientific advisory board to further develop our product pipeline in support of our mission to bring meaningful health products to market.”
The fresh funding will help Elysium expand its product portfolio and its pipeline. The company has been widely recognized for its commitment to innovation and making scientific research accessible directly available to consumers.